Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI258 in relapsed or refractory multiple myeloma with or without t(4;14)
NL-OMON35028Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dovitinib in multiple myeloma (MM), sponsored by Novartis. Primary endpoint: Extended overall response rate. Started Aug 2010; status: active, not recruiting.
02
Drugs
dovitinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON35028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35028.